Ovid Therapeutics Announces Participation in the 2020 RBC Capital Markets Virtual Global Healthcare Conference
Ovid Therapeutics Inc. (NASDAQ: OVID) announced that President and Chief Medical Officer Amit Rakhit, M.D., MBA, will participate in a fireside chat at the 2020 RBC Capital Markets Virtual Global Healthcare Conference on May 19 at 1:20 p.m. ET.
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Rhea-AI Summary
Ovid Therapeutics Inc. (NASDAQ: OVID) announced that President and Chief Medical Officer Amit Rakhit, M.D., MBA, will participate in a fireside chat at the 2020 RBC Capital Markets Virtual Global Healthcare Conference on May 19 at 1:20 p.m. ET. This session aims to discuss the company's commitment to developing transformative medicines for rare neurological diseases. Ovid's pipeline includes the investigational medicine OV101 for Angelman syndrome and Fragile X syndrome, and OV935 for rare developmental and epileptic encephalopathies in collaboration with Takeda. Details will be available through their website.
Positive
- Participation in a high-profile healthcare conference enhances visibility.
- Development of OV101 and OV935 shows commitment to addressing rare neurological diseases.
Negative
- None.
Details
News Market Reaction – OVID
The recorded move for OVID in the trading session of this news was +3.30%.
Data tracked by StockTitan Argus. Session date unavailable.
AI-generated analysis. How Rhea-AI works. Not financial advice.
NEW YORK, May 12, 2020 (GLOBE NEWSWIRE) -- Ovid Therapeutics Inc. (NASDAQ: OVID), a biopharmaceutical company committed to developing medicines that transform the lives of people with rare neurological diseases, today announced that Amit Rakhit, M.D., MBA, President and Chief Medical Officer, will participate in a fireside chat at the 2020 RBC Capital Markets Virtual Global Healthcare Conference on Tuesday, May 19, at 1:20 p.m. ET.
A live audio webcast of the discussion can be accessed through the Events & Presentations section of the Company's website at investors.ovidrx.com. An archived replay of the webcast will be available on the Company's website for two weeks following the live presentation.
About Ovid Therapeutics
Ovid Therapeutics Inc. is a New York-based biopharmaceutical company using its BoldMedicine® approach to develop medicines that transform the lives of patients with rare neurological disorders. Ovid has a broad pipeline of potential first-in-class medicines. The Company’s most advanced investigational medicine, OV101 (gaboxadol), is currently in clinical development for the treatment of Angelman syndrome and Fragile X syndrome. Ovid is also developing OV935 (soticlestat) in collaboration with Takeda Pharmaceutical Company Limited for the potential treatment of rare developmental and epileptic encephalopathies (DEE). For more information on Ovid, please visit http://www.ovidrx.com/.
Contacts
Investors and Media:
Ovid Therapeutics Inc.
Investor Relations & Public Relations
irpr@ovidrx.com
Or
Investors:
Steve Klass
Burns McClellan, Inc.
sklass@burnsmc.com
(212) 213-0006
Media:
Katie Engleman
1AB
katie@1abmedia.com
(919) 333-7722
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.